MagForce AG: MagForce USA, Inc. has Received FDA’s Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System

Written by Petra Hegmann on 13th October 2021. Posted in Client News.

• Previous
• Next